Leap Therapeutics, Inc.

Equities

LPTX

US52187K2006

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
2.66 USD -4.32% Intraday chart for Leap Therapeutics, Inc. +4.31% -35.83%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating MT
Leap Therapeutics Files $200 Million Mixed-Securities Shelf Registration MT
Leap Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Leap Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Leap Therapeutics, Inc. - Special Call
Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium CI
Transcript : Leap Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 01:30 PM
Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients CI
Mizuho Securities Adjusts Price Target on Leap Therapeutics to $12 From $20, Maintains Buy Rating MT
Leap Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Top Premarket Decliners MT
Top Premarket Decliners MT
Baird Lowers Price Target on Leap Therapeutics to $20 From $30, Maintains Outperform Rating MT
Leap Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Raymond James Adjusts Price Target on Leap Therapeutics to $18.50 From $17, Maintains Outperform Rating MT
Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients CI
Raymond James Adjusts Price Target on Leap Therapeutics to $17 From $20, Keeps Outperform Rating MT
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell Microcap Value Index CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell 3000E Value Index CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell 3000E Index CI
Leap Therapeutics, Inc.(NasdaqCM:LPTX) dropped from Russell Microcap Index CI
Leap Therapeutics to Effect 10-for-1 Reverse Stock Split MT
Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting CI
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Leap Therapeutics Completes Enrollment of Part A of Phase 2 Study of Potential Colorectal Cancer Combination Therapy MT
Chart Leap Therapeutics, Inc.
More charts
Leap Therapeutics, Inc. is a biotechnology company. The Company is focused on developing targeted and immuno-oncology therapeutics. Its advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. DKK1 modulates the Wnt/Beta-catenin and PI3kinase/AKT signaling pathways and promotes tumor proliferation, metastasis, angiogenesis, and in mediating an immune suppressive tumor microenvironment through enhancing the activity of myeloid-derived suppressor cells and downregulating NK cell ligands on tumor cells. The Company's pipeline includes FL-301, a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Claudin18.2 regulates barrier properties and contributes to cell-to-cell adhesion. It also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.66 USD
Average target price
11.75 USD
Spread / Average Target
+341.73%
Consensus
  1. Stock
  2. Equities
  3. Stock Leap Therapeutics, Inc. - Nasdaq
  4. News Leap Therapeutics, Inc.
  5. Leap Therapeutics : Mizuho Securities Starts Leap Therapeutics at Buy With $6 Price Target